kainos loboratories

4556.TTSE STANDARD

Filed as KAINOS Laboratories,Inc. (2022-06–2025-11), KAINOS Laboratories, Inc. (2024-06–2025-06)

Key numbers · FY ended 2025-03

Revenue¥5.3bn+4.9% YoY Operating income¥824m-4.8% YoY Total assets¥8.8bn+2.3% YoY EPS (basic)¥152.06-0.1% YoY

Full financial history and reports →

Stock price4556 · View chart ↗

Open the price chart on TradingView.

Latest filings

Tue, Apr 7 · JST2 filings

15:115% STAKEkainos loboratories · ASAHI KASEI THERAPEUTICS CORPORATION + 1 joint holder · 91.34% → 91.34%10:215% STAKEkainos loboratories · Mizuho Trust & Banking Co., Ltd. + 1 joint holder · 8.14% → 1.32%−6.82pp

Wed, Apr 1 · JST2 filings

16:075% STAKEkainos loboratories · Hikari Tsushin K.K. + 3 joint holders · 21.48% → 0.00%−21.48pp 15:435% STAKEkainos loboratories · Flowers Co., Ltd. + 1 joint holder · 91.34%new 91.34%

Tue, Mar 31 · JST1 filing

14:075% STAKEkainos loboratories · Akiko Sugiyama · 9.76% → 0.00%−9.76pp

All filings →

Major holders (5%+) · 3

Holder	Stake	Change	Filed
Flowers Co., Ltd.joint holder	70.72%	0.00pp	2026-04-07
ASAHI KASEI THERAPEUTICS CORPORATION	20.62%	0.00pp	2026-04-07
ASAHI KASEI PHARMA CORPORATION	20.62%	0.00pp	2026-03-31

Each holder's own ratio from its most recent large-shareholding report.